诊断学理论与实践 ›› 2026, Vol. 25 ›› Issue (04): 442-449.doi: 10.16150/j.1671-2870.2026.04.007
张静怡, 刘旭, 岳·乌日里嘎, 王蒙灿, 蔡文林, 胡克(
)
收稿日期:2026-01-01
修回日期:2026-02-15
接受日期:2026-06-18
出版日期:2026-08-25
发布日期:2026-08-31
通讯作者:
胡克 E-mail:hukejx@163.com
ZHANG Jingyi, LIU Xu, YUE Wuriliga, WANG Mengcan, CAI Wenlin, HU Ke(
)
Received:2026-01-01
Revised:2026-02-15
Accepted:2026-06-18
Published:2026-08-25
Online:2026-08-31
摘要:
目的: 分析成人链球菌属感染致脓胸患者的临床特征,以指导诊治策略制定和预后评估。方法: 回顾分析2019年12月至2025年9月间在武汉大学人民医院经胸腔积液培养和(或)血培养确诊为链球菌属感染的28例成人脓胸患者的临床特征,根据其是否存在合并症和(或)免疫抑制状态,将其分为无危险因素组(n=8)和有危险因素组(n=20),收集并比较2组患者的基线资料、临床表现以及实验室检查、病原学检查结果和治疗方案、临床转归。结果: 本研究共收治脓胸患者440例,其中链球菌属感染所致脓胸占6.4%。28例患者的CT图像表现均符合胸腔积液的特征,且大多数(19例)积液呈包裹性,临近胸膜增厚。其中,双侧脓胸最为常见(46.43%),其次为右侧(35.71%)和左侧(17.86%)。星座链球菌是链球菌属感染导致脓胸患者的主要致病菌(占50%);中间链球菌仅见于无危险因素组;其他菌属包括咽峡炎链球菌、缓症链球菌、肺炎链球菌和口腔链球菌。无危险因素组与有危险因素组患者间的平均年龄、发热比例、全身炎症指标[白细胞计数、C反应蛋白、降钙素原(procalcitonin,PCT)]差异均无统计学意义(P均>0.05)。无危险因素组有5例出现肝功能损伤,发生率高于有危险因素组的趋势(5/8比3/20,P=0.05)。2组患者培养获得的所有菌株对一线β-内酰胺类药物均敏感,2组的耐药率无统计学差异(P均>0.05)。治疗转归方面,有危险因素组与无危险因素组患者间的抗感染时间及住院时间的差异均无统计学意义,有危险因素组有3例(3/20)患者因脓胸及其引起的并发症而死亡。28例脓胸患者中,8例接受外科手术治疗的患者,无论是否存在危险因素,均好转出院。结论: 星座链球菌是导致成人脓胸的重要致病菌。无合并症和(或)免疫抑制状态的患者,肝功能损害发生率更高。治疗方面,药敏结果显示,一线β-内酰胺类药物(青霉素/头孢菌素)仍高度有效,但需警惕对克林霉素等药物的普遍耐药。对于脓胸患者,宜在充分抗感染治疗的基础上,尽早进行胸腔闭式引流。
中图分类号:
张静怡, 刘旭, 岳·乌日里嘎, 王蒙灿, 蔡文林, 胡克. 成人链球菌属感染致脓胸患者的临床特征分析[J]. 诊断学理论与实践, 2026, 25(04): 442-449.
ZHANG Jingyi, LIU Xu, YUE Wuriliga, WANG Mengcan, CAI Wenlin, HU Ke. Analysis of clinical characteristics of adult patients with empyema caused by Streptococcus infection[J]. Journal of Diagnostics Concepts & Practice, 2026, 25(04): 442-449.
表1
有无危险因素脓胸患者人口统计学及临床表现比较[n(%)]
| Parameter | Overall(n=28) | No risk factors group (n=8) | With risk factors group (n=20) | P value |
|---|---|---|---|---|
| Male | 22 (78.6) | 5 (62.5) | 17 (85.0) | 0.311 |
| Age(years)(x±s) | 59.0±14.6 | 49.6±18.8 | 62.8±11.1 | 0.059 |
| Tobacco use | 13 (46.4) | 2 (25.0) | 11 (55.0) | 0.221 |
| Alcohol use | 5 (17.9) | 1 (12.5) | 4 (20.0) | 1.000 |
| History of surgery | 8 (28.6) | 0 | 8 (40.0) | 0.063 |
| Comorbidities | ||||
| Bronchial asthma | 2 (7.1) | 0 | 2 (10.0) | 1.000 |
| Hypertension | 5 (17.9) | 0 | 5 (25.0) | 0.281 |
| Coronary heart disease | 1 (3.6) | 0 | 1 (5.0) | 1.000 |
| Diabetes | 7 (25.0) | 0 | 7 (35.0) | 0.075 |
| Congenital/Acquired solitary kidney | 2 (7.1) | 0 | 2 (10.0) | 1.000 |
| Malignancy | 8 (28.6) | 0 | 8 (40.0) | 0.063 |
| Clinical manifestations | ||||
| Cough | 20 (71.4) | 6 (75.0) | 14 (70.0) | 1.000 |
| Fever | 17 (60.7) | 7 (87.5) | 10 (50.0) | 0.099 |
| Expectoration | 16 (57.1) | 5 (62.5) | 11 (55.0) | 1.000 |
| Chest pain | 14 (50.0) | 5 (62.5) | 9 (45.0) | 0.678 |
| Dyspnea | 11 (39.3) | 3 (37.5) | 8 (40.0) | 1.000 |
| Chest tightness | 7 (25.0) | 2 (25.0) | 5 (25.0) | 1.000 |
| Abdominal pain | 5 (17.9) | 1 (12.5) | 4 (20.0) | 1.000 |
| Night sweats | 2 (7.1) | 0 (0) | 2 (10.0) | 1.000 |
| Palpitations | 2 (7.1) | 0 (0) | 2 (10.0) | 1.000 |
| Low back pain | 2 (7.1) | 1 (12.5) | 1 (5.0) | 0.497 |
| Hemoptysis | 2 (7.1) | 0 (0) | 2 (10.0) | 1.000 |
| Nausea | 1 (3.6) | 0 (0) | 1 (5.0) | 1.000 |
| Abdominal distension | 1 (3.6) | 0 (0) | 1 (5.0) | 1.000 |
| Edema | 1 (3.6) | 1 (12.5) | 0 (0) | 0.286 |
表2
有无危险因素脓胸患者实验室检查及影像学结果比较 [M (IQR)]
| Parameter | Overall (n=28) | No risk factors group (n=8) | With risk factors group (n=20) | P value |
|---|---|---|---|---|
| Peripheral blood & biochemistry | ||||
| WBC,×109 (n=27) | 11.33 (7.39, 15.84) | 11.71 (8.98, 17.63) | 10.83 (7.03, 14.44) | 0.396 |
| N,×109 (n=27) | 8.73 (6.04, 14.03) | 9.88 (7.37, 15.29) | 8.39 (4.89, 12.71) | 0.367 |
| N, % (n=27) | 84.5 (76.90, 89.05) | 84.25 (82.10, 89.08) | 86.90 (72, 89.05) | 0.441 |
| PCT, ng/mL (n=27) | 0.85 (0.22, 3.59) | 0.84 (0.30, 1.11) | 1.02 (0.16, 6.15) | 0.958 |
| CRP, mg/L (n=19) | 121.99 (90.11, 155.15) | 153.62 (148.65, 188.53) | 116.43 (87.66, 150.84) | 0.206 |
| ALT, U/L (n=28) | 31.83 (17.85, 56.00) | 61.50 (33.25, 81.75) | 28.00 (13.8, 36.75) | 0.050 |
| AST, U/L (n=28) | 29.00 (17.00, 53.00) | 50.5 (34.25, 71.50) | 25.72 (16.75, 47.88) | 0.093 |
| TBIL,umol/L(n=19) | 13.90 (8.51, 38.30) | 25.65 (11.85, 38.10) | 25.65 (11.85, 38.10) | 0.920 |
| Cr, umol/L (n=26) | 65.00 (53.50, 76.75) | 62.00 (56.00, 70.00) | 67.00 (50.71, 77.00) | 0.802 |
| DD, mg/L(n=23) | 1.94 (1.25, 3.45) | 2.71 (1.44, 4.69) | 1.91 (1.26, 2.69) | 0.485 |
| Pleural fluid analysis (n=28) | ||||
| RBC, ×1012 | 0.04 (0.02, 0.18) | 0.02 (0.00, 0.08) | 0.09 (0.02, 0.20) | 0.198 |
| WBC, ×109 | 49.42 (5.49, 129.30) | 17.48 (2.49, 71.15) | 53.38 (13.32,167.70) | 0.245 |
| N, ×109 | 34.00 (3.97, 112.90) | 13.98 (2.26, 45.79) | 46.71 (11.63, 147.60) | 0.159 |
| LYM, ×109 | 0.17 (0.10, 0.66) | 0.18 (0.04, 0.41) | 0.17 (0.01, 0.68) | 0.878 |
| TP, g/L | 21.84 (7.30, 42.95) | 42.00 (19.57, 48.26) | 16.20 (6.40, 38.50) | 0.153 |
| GLU, mmol/L | 0.39 (0.05, 0.85) | 0.25 (0.13,0.78) | 0.47 (0.09, 0.79) | 0.659 |
| LDH, U/L | 3092 (1 121, 5 820) | 2671 (487.5, 5 800) | 3512 (1 400, 5 509) | 0.552 |
| Location of empyema, n (%) | ||||
| Left-sided | 5(17.86) | 1(12.50) | 4(20.00) | 1.000 |
| Right-sided | 10(35.71) | 3(37.50) | 7(35.00) | 1.000 |
| Bilateral | 13(46.43) | 4(50.00) | 9(45.00) | 1.000 |
表3
病原学检测方法及结果、治疗手段与转归[n(%),均数±标准差]
| Parameter | Overall(n=28) | No risk factors group(n=8) | With risk factors group (n=20) | P value |
|---|---|---|---|---|
| Etiologic diagnostic methods | ||||
| Positive blood culture | 3 (10.7) | 2 (25.0) | 1 (5.0) | 0.273 |
| Positive pleural fluid culture | 25 (89.3) | 6 (75.0) | 19 (95.0) | 0.188 |
| Site of infection | ||||
| Isolated empyema | 11 (39.3) | 5 (62.5) | 6 (30.0) | 0.200 |
| Empyema + Bacterial pneumonia | 7 (25.0) | 1 (12.5) | 6 (30.0) | 0.633 |
| Empyema + Fungal pneumonia | 3 (10.7) | 1 (12.5) | 2 (10.0) | 1.000 |
| Empyema + Polymicrobial pulmonary infection | 7 (25.0) | 1 (12.5) | 6 (30.0) | 0.633 |
| Treatment modalities | ||||
| Closed-tube thoracostomy alone [n (%)] | 13 (46.4) | 3 (37.5) | 10 (50.0) | 0.686 |
| Closed-tube thoracostomy + intrapleural urokinase [n (%)] | 7 (25.0) | 2 (25.0) | 5 (25.0) | 1.000 |
| Surgical intervention* [n (%)] | 8 (28.6) | 3 (37.5) | 5 (25.0) | 0.651 |
| Clinical Outcomes | ||||
| Duration of antibiotic therapy (d) | 18.6±13.9 | 13.9±5.1 | 20.5±15.8 | 0.251 |
| Hospital stay (d) | 23.9±16.6 | 16.5±6.9 | 26.9±18.5 | 0.120 |
| Favorable recovery [n (%)] | 23 (82.1) | 7 (87.5) | 16 (80.0) | 1.000 |
| Non-resolved infection [n (%)] | 2 (7.1) | 1 (12.5) | 1 (5.0) | 0.497 |
| All-cause mortality [n (%)] | 3 (10.7) | 0 (0) | 3 (15.0) | 0.536 |
表4
有无危险因素脓胸患者感染链球菌属及耐药性比较[n(%)]
| Parameter | Overall(n=28) | No risk factors group(n=8) | With risk factors group(n=20) | P value |
|---|---|---|---|---|
| Streptococcal species | ||||
| Streptococcus constellatus | 14 (50.0) | 4 (50.0) | 10 (50.0) | 1.000 |
| Streptococcus intermedius | 3 (10.7) | 3 (37.5) | 0 (0) | 0.017 |
| Streptococcus anginosus | 6 (21.4) | 1 (12.5) | 4 (20.0) | 1.000 |
| Streptococcus pneumoniae | 1 (3.6) | 0 (0) | 1 (5.0) | 1.000 |
| Streptococcus mitis | 3 (10.7) | 0 (0) | 4 (20.0) | 0.295 |
| Streptococcus oralis | 1 (3.6) | 0 (0) | 1 (5.0) | 1.000 |
| Positive pleural fluid culture | 9 (32.1) | 3 (37.5) | 6 (30.0) | 1.000 |
| Streptococcus constellatus | 6 (21.4) | 2 (25.0) | 4 (20.0) | 1.000 |
| Streptococcus intermedius | 1 (3.6) | 1 (12.5) | 0 (0) | 0.286 |
| Streptococcus anginosus | 1 (3.6) | 0 (0) | 1 (5.0) | 1.000 |
| Streptococcus pneumoniae | 1 (3.6) | 0 (0) | 1 (5.0) | 1.000 |
| [1] |
Shen K R, Bribriesco A, Crabtree T, et al. The American Association for Thoracic Surgery consensus guidelines for the management of empyema[J]. J Thorac Cardiovasc Surg, 2017, 153(6):e129-e146.
doi: 10.1016/j.jtcvs.2017.01.030 pmid: 28274565 |
| [2] | Davies H E, Davies R J O, Davies C W H. Management of pleural infection in adults: British Thoracic Society pleural disease guideline 2010[J]. Thorax, 2010, 65(Suppl 2):ii41-ii53. |
| [3] |
Miscia M E, Lauriti G, Di Renzo D, et al. Video-assisted thoracoscopic surgery versus tube thoracostomy with fibrinolytics for treatment of empyema in children: A meta-analysis of randomized controlled studies[J]. Children, 2025, 12(9):1225.
doi: 10.3390/children12091225 URL |
| [4] |
Bobbio A, Bouam S, Frenkiel J, et al. Epidemiology and prognostic factors of pleural empyema[J]. Thorax, 2021, 76(11):1117-1123.
doi: 10.1136/thoraxjnl-2020-215267 pmid: 33785584 |
| [5] | Lisboa T, Waterer G W, Gary Lee Y C. Pleural infection: Changing bacteriology and its implications[J]. Respirolo-gy, 2011, 16(4):598-603. |
| [6] |
Ahmed R A, Marrie T J, Huang J Q. Thoracic empyema in patients with community-acquired pneumonia[J]. Am J Med, 2006, 119(10):877-883.
pmid: 17000220 |
| [7] |
Lin J, Zhang Y, Bao C, et al. The clinical features and management of empyema caused by Streptococcus constellatus[J]. Infect Drug Resist, 2022, 15:6267-6277.
doi: 10.2147/IDR.S382484 pmid: 36329986 |
| [8] |
Yang H H, Li M, Yu Q, et al. Empyema caused by Streptococcus constellatus in a patient infected with HIV: A case report and literature review[J]. AIDS Res Ther, 2024, 21(1):2.
doi: 10.1186/s12981-023-00587-z |
| [9] |
Sun J, Tong X, Liu S, et al. Clinical characteristics and mortality risk factors of Streptococcus constellatus infection: A retrospective cohort study of 390 patients[J]. J Infect Public Health, 2026, 19(1):103023.
doi: 10.1016/j.jiph.2025.103023 URL |
| [10] |
Kuryłek A, Stasiak M, Kern-Zdanowicz I. Virulence factors of Streptococcus anginosus-a molecular perspective[J]. Front Microbiol, 2022, 13:1025136.
doi: 10.3389/fmicb.2022.1025136 URL |
| [11] |
Molloy E M, Cotter P D, Hill C, et al. Streptolysin S-like virulence factors: The continuing SagA[J]. Nat Rev Microbiol, 2011, 9(9):670-681.
doi: 10.1038/nrmicro2624 pmid: 21822292 |
| [12] | Wessels M R. Capsular polysaccharide of group A Streptococcus[J]. Microbiol Spectr, 2019, 7:7.1.01. |
| [13] |
Siegman-Igra Y, Azmon Y, Schwartz D. Milleri group Streptococcus: A stepchild in the viridans family[J]. Eur J Clin Microbiol Infect Dis, 2012, 31(9):2453-2459.
doi: 10.1007/s10096-012-1589-7 URL |
| [14] |
Brouwer M C, Tunkel A R, van de Beek D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis[J]. Clin Microbiol Rev, 2010, 23(3):467-492.
doi: 10.1128/CMR.00070-09 pmid: 20610819 |
| [15] |
Dyrhovden R, Eagan T M, Fløtten Ø, et al. Pleural empye-ma caused by Streptococcus intermedius and Fusobacterium nucleatum: A distinct entity of pleural infections[J]. Clin Infect Dis, 2023, 77(10):1361-1371.
doi: 10.1093/cid/ciad378 pmid: 37348872 |
| [16] | Zohouri M, Zahid A, Silvestre A, et al. A rare case of pyopneumothorax due to Streptococcus intermediusin a pre-viously healthy woman[J]. Case Rep Pulmonol, 2025, 2025:1665286. |
| [17] | Sell R E, Juang D, et al. Streptococcus anginosus Group of bacteria as an underappreciated cause of pneumonia[J]. Open Forum Infect Dis, 2025, 12(10):ofaf538. |
| [18] |
Dhainaut J F, Marin N, Mignon A, et al. Hepatic response to sepsis: Interaction between coagulation and inflammatory processes[J]. Crit Care Med, 2001, 29:S42-S47.
doi: 10.1097/00003246-200107001-00016 pmid: 11445733 |
| [19] |
Velikova T V, Kabakchieva P P, Assyov YS, et al. Targe-ting inflammatory cytokines to improve type 2 diabetes control[J]. BioMed Res Int, 2021, 2021:7297419.
doi: 10.1155/bmri.v2021.1 URL |
| [20] | Tanaka Y. Immunosuppressive mechanisms in diabetes mellitus[J]. Nihon Rinsho, 2008, 66(12):2233-2237. |
| [21] | Al Ghamdi Z M, Boumarah D N, Alshammary S, et al. Pleural empyema as a complication of pyogenic liver abscess: Can the minimum achieve the optimal? A comparison of 3 approaches[J]. Am J Case Rep, 2021, 22:e935169. |
| [22] |
Eshghi A, Nejad N H, Mohammadzadeh A, et al. Standard treatment regimen with and without dexamethasone on outcome of children aged 3-7 years with empyema: A randomized double blind clinical trial[J]. Ital J Pediatr, 2025, 51(1):253.
doi: 10.1186/s13052-025-02102-8 pmid: 40817233 |
| [23] | Redden M D, Chin T Y, van Driel M L. Surgical versus non-surgical management for pleural empyema[J]. Cochrane Database Syst Rev, 2017, 2017(3):CD010651. |
| [24] | 王立朋, 罗杰, 李娜, 等. 星座链球菌合并脆弱拟杆菌感染引发菌血症及肝脓肿1例[J]. 中华临床感染病杂志, 2025, 18(4):305-308. |
| Wang Lipeng, Luo Jie, Li Na, et al. Co-infection with Streptococcus constellatus and Bacteroides fragilis causing bacteremia and hepatic abscess: A case report[J]. Chin J Clin Infect Dis, 2025, 18(4):305-308. | |
| [25] | 中华医学会急诊医学分会, 中国老年医学学会急诊医学分会. 急诊成人社区获得性肺炎医药协同管理抗菌治疗指南[J]. 中华急诊医学杂志, 2025, 34(6):772-781. |
| Emergency Medicine Society of Chinese Medical Association, Emergency Medicine Branch of Chinese Geriatric Society. Guideline for antibacterial therapy of adult community-acquired pneumonia in the emergency department under the physician-pharmacist collaborative mana-gement model[J]. Chin J Emerg Med, 2025, 34(6):772-781. | |
| [26] | 中国老年医学学会呼吸病学分会. 老年肺炎临床诊断与治疗专家共识(2024年版)[J]. 中华结核和呼吸杂志, 2025, 48(1):18-34. |
| Respiratory Branch of Chinese Geriatrics Society. Chinese expert consensus on the diagnosis and treatment of pneumonia in the elderly(2024 Edition)[J]. Chin J Tuberc Respir Dis, 2025, 48(1):18-34. |
| [1] | 刘静静, 魏平珠, 罗成, 俞许超, 王宏超, 吴天艺. 老年胰腺癌患者根治术后谵妄风险预测模型的构建及验证[J]. 诊断学理论与实践, 2026, 25(04): 457-466. |
| [2] | 秦惠宏, 于方圆, 蒋婕, 张天栋, 潘芬. 新生儿念珠菌血症发生及预后不良的危险因素[J]. 诊断学理论与实践, 2026, 25(03): 321-326. |
| [3] | 高一慧, 张会萍, 周毓青. 基于“产后42天”产妇腹直肌的超声两步法评估产后腹直肌分离及其相关危险因素分析[J]. 诊断学理论与实践, 2025, 24(06): 641-647. |
| [4] | 唐春花, 郭露, 张莉莉. 2025年全球卒中报告数据解读:卒中疾病负担的梯度演变与精准治理[J]. 诊断学理论与实践, 2025, 24(05): 485-497. |
| [5] | 杨梅, 廖啟安, 谭全会, 李婷婷, 张毅, 陈洁, 汤正好. 医院获得性细菌性脑膜炎患者预后不良的危险因素分析及列线图预测模型的构建[J]. 诊断学理论与实践, 2025, 24(04): 441-448. |
| [6] | 雷朝闻尉, 饶佳玲, 周梦雪, 杨虹. 胰腺脂肪沉积的危险因素及相关疾病的研究进展[J]. 诊断学理论与实践, 2025, 24(01): 72-79. |
| [7] | 邵新淋, 朱雪梅, 曹华. 结缔组织病相关间质性肺疾病危险因素及发病机制研究进展[J]. 诊断学理论与实践, 2024, 23(02): 202-209. |
| [8] | 李蕾, 吴希, 戴菁, 武文漫, 丁秋兰, 王学锋. 中国118例颅内静脉窦血栓患者的临床特点及危险因素分析[J]. 诊断学理论与实践, 2023, 22(03): 261-269. |
| [9] | 丁燕飞, 忻笑容, 周郁芬, 谢玲, 谷雷雷, 吴云林, 陈平. 上消化道溃疡伴出血患者溃疡愈合延迟的危险因素分析[J]. 诊断学理论与实践, 2022, 21(03): 312-316. |
| [10] | 梁亚丽, 赵海港, 项广宇. 应激性高血糖比值预测急性缺血性脑卒中患者溶栓治疗后1年不良预后的价值[J]. 诊断学理论与实践, 2021, 20(06): 562-566. |
| [11] | 刘安平, 凌枫, 史超, 孙璟. 上海社区老年脑卒中患者跌倒风险因素分析及风险识别模型的建立[J]. 诊断学理论与实践, 2021, 20(05): 475-479. |
| [12] | 施仲伟. 回眸过去30年全球和中国的心血管疾病负担及其危险因素——1990年至2019年全球心血管疾病负担及其危险因素报告解读[J]. 诊断学理论与实践, 2021, 20(04): 349-355. |
| [13] | 吴洁, 冯媛媛, 任妍, 曹久妹. 基于冠状动脉造影检查的高龄老年人群发生冠心病的危险因素调查及相应诊断模型的建立[J]. 诊断学理论与实践, 2021, 20(02): 201-206. |
| [14] | 林雨轩, 赵延华, 王筱婧. 丙泊酚镇静下无痛胃镜术中低氧血症的发生率及危险因素分析[J]. 诊断学理论与实践, 2020, 19(06): 594-599. |
| [15] | 魏晓敏, 张媛媛, 董樑, 夏敬文, 龚益, 喻永平, 李圣青. 真实世界中肺栓塞后慢性血栓栓塞性肺动脉高压的发病及相关危险因素前瞻性研究[J]. 诊断学理论与实践, 2019, 18(1): 37-43. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||